critique

Hypothesis 1 has the best systems logic, but it is one step removed from the phrase "specifically modulate ADORA2A signaling." Reduced inflammation can improve mood behavior without ADORA2A being the decisive node, so the claim needs pharmacologic rescue with selective ADORA2A agonists/antagonists.

Hypothesis 2 is attractive because it could generate specificity upstream of the receptor, but there is a major promiscuity risk. Parthenolide is an electrophilic sesquiterpene lactone and may alkylate many proteins; any apparent effect on transport or metabolism must survive chemoproteomic selectivity profiling.

Hypothesis 3 is the most novel and the weakest. Membrane-coupling stories are easy to tell after the fact and hard to falsify unless direct signaling assays show preserved receptor abundance with changed efficacy. If ADORA2A knockout or blockade does not blunt the antidepressant phenotype, then all three models overstate receptor dependence.